Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Feb 2018 Planned number of patients changed to 41.
- 06 Feb 2018 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 06 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.